Skin irritation patch test to evaluate skin safety of Cannabidiol (CBD) in healthy Female subjects
- Conditions
- Health Female
- Registration Number
- JPRN-UMIN000042977
- Lead Sponsor
- Showa University School of Medicine Department of Clinical Pharmacology
- Brief Summary
In the range of CBD concentrations of 0% to 1.5%, CBD was not observed of any skin irritating adverse effects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 10
Not provided
) Those who have a history of evaluation of this test and considered to have an impact on safety, such as Drug abuse/ dependence, alcohol abuse/ dependence, heart, liver, kidney, lung, eye, blood, digestive diseases, etc. 2) A person who has a history of allergies to drugs or has a specific constitution (Alcohol hypersensitivity, etc.) 3) Those who may use the drug (antihistamines, adrenal cortical hormone agents) within one week before administered the study drug 4) Pregnant or nursing women 5) Those who are within 3 months of participating in other clinical trials 6) In addition, those who are deemed unsuitable for this study by the physician responsible for the research or the doctor sharing the research
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of skin irritation based on the ICDRG (International Contact Dermatitis Research Group) Standards
- Secondary Outcome Measures
Name Time Method Safety: Evaluated for all adverse events